Iovance Biotherapeutics (IOVA) Q2 2024 earnings summary

Executive summary

• Achieved $31.1 million in Q2 2024 product revenue from Amtagvi and Proleukin, marking the first commercial TIL cell therapy sales following FDA approval in February 2024 for advanced melanoma.

• Over 55 patients infused with Amtagvi since April 2024, with more than 30 in Q3 to date, and over 50 ATCs onboarded, indicating strong launch momentum.

• ATC network expanded to over 50 centers, targeting at least 70 by year-end, ensuring broad patient access.

• Submitted marketing authorization applications in EU, UK, Canada, Australia, and Switzerland for global expansion.

• Strong clinical pipeline with ongoing registrational trials in melanoma, NSCLC, and endometrial cancer, plus next-generation TIL therapies in development.

Financial highlights

• Q2 2024 net product revenue was $31.1 million (Amtagvi $12.8M, Proleukin $18.3M), up from $0.2 million in Q2 2023.

• Q2 2024 net loss was $97.1 million ($0.34/share), improved from $106.5 million ($0.47/share) in Q2 2023.

• Cost of sales for Q2 2024 was $31.4 million, up from $2.1 million in Q2 2023, reflecting commercial manufacturing ramp-up.

• R&D expenses decreased to $62.1 million in Q2 2024 from $86.3 million in Q2 2023, due to transition to commercial manufacturing.

• SG&A expenses rose to $39.6 million in Q2 2024, up from $21.9 million in Q2 2023, supporting commercialization.

Outlook and guidance

• Q3 2024 product revenue expected at $53–$55 million; full-year 2024 guidance is $160–$165 million; 2025 product revenue projected at $450–$475 million.

• Gross margins expected to exceed 70% over the next several years as scale and efficiencies improve.

• Cash position of $449.6 million as of July 24, 2024, sufficient to fund operations into early 2026.

• Full-year 2024 cash burn guidance is $320–$340 million, excluding one-time expenses.

• Revenues from Amtagvi and Proleukin may not be sufficient to generate positive operational cash flows in the near term.